If you have a history of allergies (asthma, eczema, allergic rhinitis, food allergy), persistent unexplained gastrointestinal symptoms, suspected parasitic infection (particularly if you've travelled to endemic regions or recently immigrated to Sweden), or are evaluating reasons for recurrent infections or unusual inflammatory symptoms, an eosinophil count is a simple and informative baseline.

Eosinophil testing is especially useful if you are being considered for modern biologic therapy in severe asthma or COPD, because blood eosinophil levels guide treatment selection and predict response. It's also relevant if you have taken medications known to cause drug hypersensitivity reactions (antibiotics, anticonvulsants, NSAIDs, allopurinol, sulfonamides, and many others) and have developed rash, fever, or systemic symptoms, as drug reaction with eosinophilia and systemic symptoms (DRESS) can present with eosinophilia.

Unlike markers requiring fasting or specific timing, the eosinophil count is part of every standard white blood cell panel done by Swedish vårdcentral labs, making it accessible and familiar to clinicians across primary and secondary care.

• Flags type-2 immune activation directly. Elevated eosinophils indicate active IL-5-driven immune response — whether from allergy, parasitic infection, or eosinophilic disease — providing a biological window into type-2 inflammation without requiring expensive specialized testing.

• Identifies allergic and parasitic disease. Persistent eosinophilia prompts investigation for allergic disease (asthma, eczema, rhinitis) or parasitic infection, particularly in returning travellers and recent immigrants to Sweden where parasitic exposure may have occurred prior to arrival.

• Predicts response to biologic therapy. In severe asthma and COPD, blood eosinophil count is the key biomarker guiding selection of IL-5-targeting biologics (mepolizumab, benralizumab) or IL-4Rα antagonists (dupilumab). Patients with eosinophilia ≥150 x10^9/L show superior response to these therapies; testing informs personalized medicine.

• Detects drug hypersensitivity and immune-mediated reactions. Drug reaction with eosinophilia and systemic symptoms (DRESS) and other drug-induced eosinophilic syndromes present with elevated eosinophils. Early detection can guide drug withdrawal and prevent progression to severe organ involvement.

• Raises suspicion for rare hematologic neoplasms. Persistent unexplained eosinophilia (>1.5 x10^9/L) warrants investigation for clonal eosinophilic neoplasms, hypereosinophilic syndrome, or other hematologic malignancy, ensuring timely specialist referral.

• Tracks immune response and treatment efficacy. Eosinophil count falls reliably with effective anti-IL-5 biologic therapy, allergy management, or parasite treatment, making it a useful real-time marker of intervention response.

The biology of eosinophils and IL-5 signaling. Eosinophils are granulocytes — specialized white blood cells packed with cytotoxic granules containing proteins (major basic protein, eosinophil peroxidase, eosinophil-derived neurotoxin) designed to kill parasites and modulate immune inflammation. Their production and survival are tightly controlled by interleukin-5 (IL-5), a cytokine produced by type-2 helper T cells (Th2 cells) and innate lymphoid cells (ILC2s). In the presence of allergens, parasitic antigens, or IL-5-producing inflammation, bone marrow eosinophil production ramps up, and eosinophils traffic to tissue (lung, gut, skin) and circulate in blood.

Two distinct immune roles: parasites and allergy. Evolutionarily, eosinophils evolved to defend against parasitic infection — their granule proteins are exquisitely toxic to worms and helminths. In modern Western populations where parasitic exposure is minimal, eosinophils are predominantly recruited by type-2 allergic responses. High IL-5 drives eosinophil accumulation in airways (allergic asthma), skin (eczema, atopic dermatitis), nose and sinuses (allergic rhinitis), and gut (eosinophilic esophagitis and gastroenteritis). This is why eosinophilia clusters with allergic disease and why IL-5-targeted biologics are transformative in allergic asthma.

Clinical distinction: blood eosinophils vs tissue eosinophilia. The blood eosinophil count reflects systemic type-2 immune activation but may not equal tissue burden — someone with high blood eosinophils may have minimal symptoms if eosinophils are trafficked to tissue. Conversely, tissue-localized eosinophilic disease (eosinophilic esophagitis, localized skin eosinophilia) may occur with normal blood eosinophils. Blood eosinophil count is nonetheless highly predictive of systemic allergic burden and guides medical therapy.

• Identifies hidden allergic and parasitic disease. Many people with chronic symptoms (fatigue, recurrent infections, gastrointestinal symptoms, chronic cough, itching) never have eosinophils measured. An elevated eosinophil count can unmask allergic asthma, eosinophilic esophagitis, or unsuspected parasitic infection — conditions that are treatable once recognized.

• Guides precision medicine in severe respiratory disease. Modern asthma and COPD management uses eosinophil-guided therapy: patients with eosinophilia ≥150 x10^9/L (or ≥300 x10^9/L depending on the biologic) show marked improvement with IL-5 or IL-4Rα antagonists, while those without eosinophilia do not respond to these agents. This is a validated example of biomarker-driven precision medicine that reduces exacerbations, steroid dependence, and mortality.

• Detects rare but serious hematologic and systemic disease. Persistent eosinophilia (>1.5 x10^9/L) without obvious cause (no parasites, no allergy history, no offending drug) is unusual and signals possible hypereosinophilic syndrome (HES), clonal eosinophilic neoplasm, or other hematologic malignancy requiring specialist evaluation and flow cytometry.

• Screens for drug-induced immune reactions. DRESS and other drug hypersensitivity syndromes present with eosinophilia alongside rash, fever, and lymphadenopathy. Early eosinophil elevation can prompt drug withdrawal before progression to hepatic or renal injury.

• Standard Swedish clinical reference (<0.5 x10^9/L): Most Swedish laboratory reference ranges set the upper limit of normal at 0.4–0.5 x10^9/L. Values below this are reported as normal on standard reports and carry no clinical concern.

• Mild elevation (0.5–1.5 x10^9/L): This range is common in allergic individuals and does not mandate investigation on its own. However, if accompanied by symptoms (rash, asthma exacerbations, gastrointestinal symptoms) or known allergy history, further evaluation for allergic disease may be warranted. This range may also transiently occur post-infection or with certain medications.

• Hypereosinophilia (≥1.5 x10^9/L): Persistent elevation at or above 1.5 x10^9/L is abnormal and warrants investigation. Common causes include parasitic infection, allergic disease, drug reaction, autoimmune disease (eosinophilic granulomatosis with polyangiitis, eosinophilic esophagitis), or hematologic neoplasm. Values >5–10 x10^9/L are unusual and carry higher suspicion for clonal disease or systemic infection.

For longevity and preventive health, an eosinophil count <0.5 x10^9/L is optimal and reflects a stable immune baseline. Any persistent elevation above 0.5 x10^9/L, especially if new or rising on serial testing, deserves clinical correlation and investigation. The delta matters: a rise from 0.3 to 1.2 x10^9/L over months may signal emerging allergic disease or parasitic exposure.

Low or absent (<0.1 x10^9/L). This is normal and may be more common in acute infection or during acute stress when cortisol-driven demargination of neutrophils suppresses eosinophil release from bone marrow. It is not a disease state and reflects appropriate immune homeostasis.

Normal (0.1–0.5 x10^9/L). This range indicates a stable, non-activated type-2 immune state. You are not mounting a significant allergic or parasitic response. If you have no symptoms of allergy or unexplained systemic symptoms, this is reassuring. If you have chronic symptoms (persistent cough, gastrointestinal symptoms, fatigue) with a normal eosinophil count, the cause is likely non-immune (metabolic, cardiovascular, or other system-level dysfunction) rather than allergy or parasitic infection.

Mildly elevated (0.5–1.5 x10^9/L). This suggests low-grade type-2 immune activation, most commonly from allergic disease, or possibly recent parasitic exposure. If you have asthma, eczema, allergic rhinitis, or food allergy, mild eosinophilia is expected and reflects disease activity. If you are asymptomatic, it may represent subclinical allergy or a transient response to infection. If eosinophils are persistently 1.0–1.5 x10^9/L, investigation for eosinophilic esophagitis or other tissue-localized eosinophilic disease may be warranted.

Markedly elevated (>1.5 x10^9/L). This level is abnormal and warrants investigation. The differential diagnosis includes: (1) allergic asthma or other allergic disease (especially if accompanied by respiratory or cutaneous symptoms); (2) parasitic infection (ask about recent travel or current gastrointestinal symptoms); (3) drug reaction (review medication list for common culprits: antibiotics, anticonvulsants, NSAIDs, allopurinol); (4) eosinophilic esophagitis or gastroenteritis (ask about dysphagia or recurrent GI symptoms); (5) autoimmune disease (eosinophilic granulomatosis with polyangiitis — EGPA, formerly Churg-Strauss); (6) hematologic malignancy or clonal eosinophilic neoplasm (less common but requires exclusion). Values >5 x10^9/L are unusual in non-neoplastic settings and should raise suspicion for clonal or hematologic disease.

Factors that influence eosinophils. Acute infection (bacterial or viral) typically suppresses eosinophils temporarily. Corticosteroid therapy (systemic or high-dose inhaled) rapidly lowers eosinophils via apoptosis and demargination suppression; eosinophils rebound over days to weeks after steroid cessation. Allergic season (pollen exposure) can transiently elevate eosinophils. Recent intense exercise or acute stress can cause temporary suppression. Parasitic infection causes sustained elevation that persists until the parasite is cleared. Pregnancy physiologically raises baseline eosinophils slightly; interpret with this in mind. Menstrual cycle does not significantly affect eosinophils.

• Allergic disease. Type-2 Th2 and ILC2 immune activation in response to environmental allergens (inhaled pollens, dust mites, pet dander, mold) or food allergens drives IL-5 production, raising blood eosinophils. Allergic asthma, allergic rhinitis, eczema (atopic dermatitis), and food allergy all correlate with elevated eosinophils. This is the most common cause of mild-to-moderate eosinophilia in wealthy nations.

• Parasitic infection. Nematodes (roundworms, hookworms), trematodes (flukes), and some cestodes (tapeworms) trigger type-2 immune responses and marked eosinophilia. This remains relevant in Sweden among individuals who have travelled to endemic regions (tropical Africa, Southeast Asia, Central/South America) or recently immigrated from areas with high parasitic prevalence. Stool microscopy and serology (anti-parasitic antibodies) can confirm parasitic infection.

• Drug hypersensitivity and DRESS. Antibiotics (penicillins, cephalosporins, sulfonamides), anticonvulsants (phenytoin, carbamazepine, lamotrigine), NSAIDs, allopurinol, and numerous other medications can trigger drug reaction with eosinophilia and systemic symptoms (DRESS). Eosinophilia clusters with fever, rash, lymphadenopathy, and hepatic or renal dysfunction. Drug withdrawal is the primary treatment; recognition via eosinophilia is critical.

• Eosinophilic gastrointestinal disorders. Eosinophilic esophagitis (EoE), eosinophilic gastritis, and eosinophilic colitis feature infiltration of the GI mucosa with eosinophils, often accompanied by elevated blood eosinophils. These conditions cause dysphagia, food impaction (EoE), epigastric pain, nausea, or chronic diarrhea. They are increasingly recognized in Sweden and respond to topical corticosteroids and dietary elimination.

• Autoimmune and systemic disease. Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) is characterized by marked eosinophilia (>1.5 x10^9/L or >10% of WBC) plus asthma, vasculitis, and multi-organ involvement. Eosinophils can also be elevated in systemic lupus erythematosus (SLE), scleroderma, and other connective tissue diseases. These are less common but require specialist evaluation.

• Hematologic neoplasm and hypereosinophilic syndrome. Clonal eosinophilic neoplasms (chronic eosinophilic leukemia), hypereosinophilic syndrome (HES — defined as eosinophils >1.5 x10^9/L for >6 months without secondary cause), and other myeloid malignancies present with persistent marked eosinophilia. Flow cytometry and cytogenetics (karyotype, FIP1L1-PDGFRA fusion in some cases) help distinguish clonal from reactive eosinophilia.

Identify and manage allergic triggers. If eosinophilia is allergic in nature, allergen identification and avoidance are the first levers. Environmental controls (HEPA filtration, dust mite-proof bedding covers, pet avoidance) reduce allergen exposure. Intranasal corticosteroids and antihistamines suppress Th2 activation and lower airway eosinophils. In allergic asthma, inhaled corticosteroids directly suppress eosinophil recruitment to airways. For food allergy-driven eosinophilia, allergen elimination diet guided by serology and clinical history is effective.

Parasite diagnosis and treatment. If parasitic infection is suspected (based on travel history, gastrointestinal symptoms, or marked eosinophilia), stool microscopy, serology, or molecular testing can confirm diagnosis. Antiparasitic medications (albendazole, mebendazole, ivermectin, praziquantel — depending on parasite species) are highly effective and rapidly normalize eosinophils once the parasite is eradicated. This is why travel history is critical in evaluating new eosinophilia.

Drug review and cessation. If eosinophilia emerged temporally with a new medication, particularly antibiotics, anticonvulsants, NSAIDs, or allopurinol, drug withdrawal is the primary intervention. Eosinophils typically fall over days to weeks after offending drug cessation. If DRESS or other severe drug hypersensitivity is suspected (rash, fever, lymphadenopathy, hepatic involvement), urgent specialist evaluation is warranted.

Biologic therapy in severe asthma and COPD. In severe eosinophilic asthma (blood eosinophils ≥150 x10^9/L) refractory to inhaled corticosteroids and long-acting beta-2 agonists, IL-5-targeting biologics (mepolizumab, benralizumab) or IL-4Rα antagonists (dupilumab) are highly effective and reduce eosinophil counts dramatically. These are specialist-prescribed therapies that are allocated on the basis of eosinophil-guided stratification. Similarly, in COPD with significant eosinophilia, these agents reduce exacerbations and steroid burden.

Investigation of persistent unexplained eosinophilia. If eosinophils are persistently elevated without identifiable cause (no parasites, no allergy history, no drug trigger, no DRESS features), flow cytometry and cytogenetic evaluation (to exclude clonal eosinophilic neoplasm) are warranted. Specialist hematology evaluation ensures rare but important diagnoses are not missed. Imaging (chest X-ray, abdominal ultrasound) may also be indicated if there is systemic symptomatology.

The right approach depends on the underlying cause — which is why interpreting eosinophils in clinical context (symptoms, travel history, medication list, associated markers like hs-CRP and WBC differential) is essential. A Loovi longevity doctor can synthesize the full picture during consultation.

A single eosinophil count tells you there is type-2 immune activation but not why, where, or how severe. An eosinophil count of 1.2 x10^9/L could reflect mild allergic asthma (easily managed with inhaled steroids), parasitic infection (requiring antiparasitic drugs), drug hypersensitivity (requiring drug withdrawal), or early clonal disease (requiring hematology evaluation). Without clinical context and related markers, you cannot distinguish between these scenarios.

The full picture requires paired assessment: hs-CRP contextualizes whether inflammation is type-2 allergic (eosinophilia high, hs-CRP low) or type-1 systemic (hs-CRP elevated); total WBC and differential count distinguish between eosinophil-predominant and mixed elevation; travel history and food/environmental exposure history guide parasitic and allergic workup; medication review flags drug reactions. In some cases, additional testing (parasite serology, allergen-specific IgE, flow cytometry, or imaging) is warranted.

The Loovi Membership measures 120+ biomarkers annually, including complete blood count with differential (WBC, eosinophils, neutrophils, lymphocytes, basophils, monocytes), inflammatory markers (hs-CRP, ESR), and metabolic context (HbA1c, fasting glucose, liver and kidney function). Paired with unrushed 1-on-1 longevity doctor consultations, clinical assessment, and when needed, specialist referral coordination, Loovi ensures abnormal eosinophil findings are interpreted in full context and that rare diagnoses are not missed. From 295 SEK/month, Friskvårdsbidrag-approved, with drop-in testing at 80+ Swedish clinics and results in 3 days.